Skip to main page content
U.S. flag

An official website of the United States government

Dot gov

The .gov means it’s official.
Federal government websites often end in .gov or .mil. Before sharing sensitive information, make sure you’re on a federal government site.

Https

The site is secure.
The https:// ensures that you are connecting to the official website and that any information you provide is encrypted and transmitted securely.

Access keys NCBI Homepage MyNCBI Homepage Main Content Main Navigation

Search Page

Filters

My NCBI Filters

Results by year

Table representation of search results timeline featuring number of search results per year.

Year Number of Results
2002 1
2003 4
2004 5
2005 6
2006 2
2007 2
2008 2
2009 6
2010 5
2011 12
2012 10
2013 7
2014 9
2015 19
2016 11
2017 14
2018 11
2019 11
2020 20
2021 14
2022 13
2023 15
2024 6

Text availability

Article attribute

Article type

Publication date

Search Results

177 results

Results by year

Filters applied: . Clear all
Page 1
TP53 DNA binding domain mutational status and rituximab-based treatment are independent prognostic factors for pediatric Burkitt lymphoma patients stratification.
Martire G, Lovisa F, Carraro E, Rizzato D, Cesaro S, Mura RM, Tondo A, Bertolin C, Boaretto F, Salviati L, Biffi A, Pillon M, Mussolin L. Martire G, et al. Among authors: pillon m. Haematologica. 2024 Feb 22. doi: 10.3324/haematol.2023.284868. Online ahead of print. Haematologica. 2024. PMID: 38385281 Free article.
Large B-cell lymphoma-IRF4+ in children and young people: time to reduce chemotherapy in a rare malignant mature B-cell neoplasm?
Huibers M, Abla O, Andrés M, Balagué O, Beishuizen A, Carraro E, Chiang A, Csóka M, David BA, de Ville de Goyet M, Gilad G, Hori D, Kotecha RS, Kabickova E, Klapper W, Miakova N, Minard-Colin V, Nakazawa A, Pillon M, Rigaud C, Salaverria I, Tölle I, Verdú-Amorós J, von Mersi H, Wössmann W, Burkhardt B, Attarbaschi A. Huibers M, et al. Among authors: pillon m. Blood Adv. 2024 Mar 26;8(6):1509-1514. doi: 10.1182/bloodadvances.2023012109. Blood Adv. 2024. PMID: 38290136 Free PMC article. No abstract available.
Correction to: Large B-cell lymphoma with IRF4 rearrangement: a multi-centric study with focus on potential misleading phenotypes.
Pizzi M, Bongiovanni L, Lorenzi L, Righi S, Scarmozzino F, Balzarini P, Santoro L, Mussolin L, Carraro E, Pillon M, Bonaldi L, Vianello F, Agostinelli C, Ponzoni M, Dei Tos AP, Sabattini E. Pizzi M, et al. Among authors: pillon m. Virchows Arch. 2024 Mar;484(3):549. doi: 10.1007/s00428-024-03751-6. Virchows Arch. 2024. PMID: 38289502 No abstract available.
Large B-cell lymphoma with IRF4 rearrangement: a multi-centric study with focus on potential misleading phenotypes.
Pizzi M, Bongiovanni L, Lorenzi L, Righi S, Scarmozzino F, Balzarini P, Santoro L, Mussolin L, Carraro E, Pillon M, Bonaldi L, Vianello F, Agostinelli C, Ponzoni M, Dei Tos AP, Sabattini E. Pizzi M, et al. Among authors: pillon m. Virchows Arch. 2024 Mar;484(3):521-526. doi: 10.1007/s00428-023-03689-1. Epub 2023 Nov 14. Virchows Arch. 2024. PMID: 37962684
Quantitative assessment of minimal residual disease for monitoring of paediatric patients with relapsed/refractory anaplastic large-cell lymphoma treated with brentuximab vedotin: A case series.
Contarini G, Carraro E, Lovisa F, Martire G, Lo Nigro L, Sala A, Pillon M, Mussolin L. Contarini G, et al. Among authors: pillon m. Br J Haematol. 2024 Jan;204(1):352-355. doi: 10.1111/bjh.19151. Epub 2023 Oct 11. Br J Haematol. 2024. PMID: 37822050 No abstract available.
MiR-146a-5p enrichment in small-extracellular vesicles of relapsed pediatric ALCL patients promotes macrophages infiltration and differentiation.
Garbin A, Contarini G, Damanti CC, Tosato A, Bortoluzzi S, Gaffo E, Pizzi M, Carraro E, Lo Nigro L, Vinti L, Pillon M, Biffi A, Lovisa F, Mussolin L. Garbin A, et al. Among authors: pillon m. Biochem Pharmacol. 2023 Sep;215:115747. doi: 10.1016/j.bcp.2023.115747. Epub 2023 Aug 15. Biochem Pharmacol. 2023. PMID: 37591448
Current practices of follow-up programs for childhood cancer survivors in Italy.
Terenziani M, Tozzi AE, Diaco L, Biasin E, Cattoni A, Croci I, Fraschini D, Giorgiani G, Haupt R, Muraca M, Pillon M, Sironi G, Valsecchi MG, Mastronuzzi A. Terenziani M, et al. Among authors: pillon m. Tumori. 2023 Dec;109(6):555-561. doi: 10.1177/03008916231185981. Epub 2023 Jul 12. Tumori. 2023. PMID: 37434559 Free PMC article.
Italian pediatric intensive care units admitting critically ill cancer children: results from a national survey.
Martinato M, Comoretto RI, Biban P, Zanonato E, Simonini A, Montaguti A, Gitto E, Caramelli F, Ferrario S, Sagredini R, Alaimo N, Zito Marinosci G, Rossetti E, Cecchetti C, L'erario M, Vasile B, Ivani G, Bonanomi E, Astuto M, Gregori D, Mondardini MC, Amigoni A; OncoTIPnet Study Group. Martinato M, et al. Minerva Anestesiol. 2023 Oct;89(10):850-858. doi: 10.23736/S0375-9393.23.17329-9. Epub 2023 Jun 28. Minerva Anestesiol. 2023. PMID: 37378625
Pediatric gray zone lymphoma according to the 2022 WHO classification: An Italian cohort study.
Restivo GA, Farruggia P, Pillon M, Mascarin M, Elia C, Recupero S, Muggeo P, Cagnazzo C, Onofrillo D, Mura R, Furfari I, Trizzino A, Bertolini P, Sala A, De Santis R, Galimberti D, Schiavello E, Carraro E; Emanuele Stefano Giovanni D'Amore. Restivo GA, et al. Among authors: pillon m. Pediatr Blood Cancer. 2023 May 30:e30481. doi: 10.1002/pbc.30481. Online ahead of print. Pediatr Blood Cancer. 2023. PMID: 37254478
Effect of rituximab on immune status in children with mature B-cell non-Hodgkin lymphoma: a prespecified secondary analysis of the Inter-B-NHL Ritux 2010 trial.
Alexander S, Aupérin A, Bomken S, Csóka M, Kazanowska B, Chiang AK, Andres M, Uyttebroeck A, Burke GAA, Zsiros J, Pillon M, Bollard CM, Mussolin L, Verdu-Amoros J, Neven B, Barkauskas DA, Wheatley K, Patte C, Gross TG, Minard-Colin V; Children's Oncology Group; European Intergroup for Childhood Non-Hodgkin's Lymphoma. Alexander S, et al. Among authors: pillon m. Lancet Haematol. 2023 Jun;10(6):e445-e457. doi: 10.1016/S2352-3026(23)00062-5. Epub 2023 Apr 21. Lancet Haematol. 2023. PMID: 37094596 Clinical Trial.
177 results